Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting
February 16, 2023 10:30 ET
|
Cue Biopharma, Inc.
Collaboration with the laboratory of Dr. Michael Dustin elucidates the mechanism of action of Immuno-STATs in activating disease-specific T cells by mimicking the natural formation of immune synapses ...
Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board
February 16, 2023 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma to Present at Two February 2023 Scientific Conferences
February 01, 2023 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma Announces Chief Medical Officer Transition
January 23, 2023 08:00 ET
|
Cue Biopharma, Inc.
Matteo Levisetti, M.D., promoted to Chief Medical Officer, effective January 17, 2023Acting CMO Kenneth Pienta, M.D., to transition to a clinical advisory role BOSTON, Jan. 23, 2023 (GLOBE...
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
November 22, 2022 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma Reports Third Quarter 2022 Financial Results
November 14, 2022 16:01 ET
|
Cue Biopharma, Inc.
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
November 14, 2022 08:20 ET
|
Cue Biopharma, Inc.
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 10, 2022 09:00 ET
|
Cue Biopharma, Inc.
Overall response rate (ORR) of 40% and a clinical benefit rate (CBR) of 70% observed to date in first line (1L) recurrent/metastatic HNSCC patients treated with CUE-101 at the recommended Phase 2 dose...
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
November 09, 2022 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma to Host Business Update Call and Webcast
November 07, 2022 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...